Global Psoriatic Arthritis Therapeutics Market Report and Forecast 2023-2031
Global Psoriatic Arthritis Therapeutics Market Outlook
The growth of the global psoriatic arthritis therapeutics market size is being driven by the increasing prevalence of psoriatic arthritis and increasing awareness about the disease across the globe. The market value is anticipated to grow at a CAGR of 6.5% during the forecast period of 2023-2031.
Psoriatic Arthritis Therapeutics: Introduction
Psoriatic arthritis is a type of inflammatory arthritis that affects some individuals with psoriasis, a skin condition that causes red, scaly patches on the skin. Psoriatic arthritis can cause joint pain, stiffness, and swelling, as well as damage to joints and other parts of the body. It can also cause nail changes and eye problems. Psoriatic arthritis affects both men and women and can occur at any age, but typically develops in people between the ages of 30 and 50. The exact cause of psoriatic arthritis is unknown, but it is believed to be an autoimmune disorder. There is no cure for psoriatic arthritis, but treatment can help manage symptoms and prevent joint damage.
Psoriatic Arthritis: Epidemiology
Psoriatic arthritis is a chronic inflammatory disease that affects the joints and the skin. The exact prevalence of psoriatic arthritis is unknown, but it is estimated to affect approximately 0.3% to 1% of the general population worldwide. It affects both men and women equally, and typically develops between the ages of 30 and 50. It is more common in people with psoriasis, a skin condition that causes red, scaly patches to appear on the skin.
Global Psoriatic Arthritis Therapeutics Market Segmentations
Market Breakup by Drug Class
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Disease-modifying antirheumatic drugs (DMARDs)
- Immunosuppressants
- Biological Agents
- Others
Market Breakup by Product Type
- Prescription
- Over The Counter
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Global Psoriatic Arthritis Therapeutics Market Scenario
Psoriatic arthritis is a chronic inflammatory arthritis that affects people with psoriasis. The global psoriatic arthritis therapeutics market is expected to experience significant growth in the forecast period from 2023 to 2031. The increasing prevalence of psoriatic arthritis, rising awareness about the disease, and the introduction of novel therapeutics are the major factors driving the market growth.
By route of administration, the market is segmented into oral, parenteral, and others. The parenteral segment is expected to witness significant growth in the forecast period due to the increasing use of biologics, which are mainly administered through the parenteral route.
Geographically, North America held the largest share of the psoriatic arthritis therapeutics market in 2020, followed by Europe and Asia Pacific. The increasing prevalence of psoriatic arthritis in North America, coupled with the availability of advanced healthcare infrastructure and favourable reimbursement policies, are the major factors contributing to the dominance of this region.
In the forecast period, Asia Pacific is expected to witness significant growth due to the increasing prevalence of psoriatic arthritis in the region, rising healthcare expenditure, and growing awareness about the disease.
Key Players in the Global Psoriatic Arthritis Therapeutics Market
The report gives an in-depth analysis of the key players involved in the global psoriatic arthritis therapeutics market. The companies included in the market are as follows:
- AbbVie Inc.
- Janssen Global Services, LLC (Johnson & Johnson)
- Novartis AG
- Amgen Inc.
- Biogen Inc.
- Pfizer Inc.
- Eli Lilly and Company
- UCB S.A.
- Bristol-Myers Squibb Company
- Merck & Co. Inc.